Why pay $100B for AstraZeneca? Let Pfizer's CEO count the reasons

Save

Pfizer considers itself a megamerger expert. And it's hoping to prove that with another megadeal–a $100-billion-or-so buyout of AstraZeneca. After last week's headlines about a possible buyout, both companies confirm that Pfizer is hot to trot and ready to parley.